Featured

Status

All Statuses
  • Active, not recruiting36

Health Topics

Any Category
Diseases
Clear Filters

Search Clinical Trials

36 Results
Active, Not Recruiting
MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of Central Nervous System (CNS) Tumors
A one-time assessment will be conducted for all participants through the Assessment Center website. No treatment or intervention will be provided. Two websites will be set up (Site A and …
Baylor Role: Collaborator
Active, Not Recruiting
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
The patient will give blood to make TAA-specific cytotoxic T cells in the lab. These cells will be grown and frozen. If the TAA-specific cytotoxic T cells can be made, …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Administration of Donor T Cells With the Caspase-9 Suicide Gene
If the patient is doing well after the stem cell transplant, and does not have severe GvHD, s/he will be eligible to receive the special "iCasp9" T cells from Day …
Baylor Role: Lead Sponsor
Active, Not Recruiting
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
The EBV CTLs will be made for specific patients. First blood will be collected from the patient and then the the CD30 chimeric-EBV CTLs will be created in the lab. …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator
Active, Not Recruiting
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
WHAT IS THE OVERALL TREATMENT PLAN AND HOW MANY VACCINATIONS WILL THE PATIENT RECEIVE? There will be several injections of the vaccine scheduled. The first injection will be given 3 …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome
This study is one of three projects of an NIH Rare Disease Clinical Research Consortium focused on brain blood vessel malformations in three different rare diseases. The focus of this …
Baylor Role: Collaborator
Active, Not Recruiting
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Because the cells have a new gene in them the patient will be followed for a total of 15 years to see if there are any long term side effects …
Baylor Role: Lead Sponsor
Active, Not Recruiting
T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL
The patient or their donor will give us blood to make CD19-CD28 chimeric receptor T cells and CD19 chimeric-EBV specific T cells in the laboratory. These cells are grown and …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role: Lead Sponsor